Amycretin mastery course
Unit 8 of 12

The obesity drug landscape

Amycretin entered the most active area of drug development in a generation, alongside approved incretin drugs and a…

Where amycretin sits in a crowded field

Amycretin entered the most active area of drug development in a generation, alongside approved incretin drugs and a wave of investigational amylin-based agents. The question everyone asks is how it compares.

The answer has to start with a fact that is easy to skip: in the sources this course cites, no randomised trial has compared amycretin with another active drug. Everything in this unit is either an indirect estimate or a statement about the shape of the evidence, and this unit is mostly about reading indirect estimates without being fooled by them.

Key terms

The only cross-agent estimate there is

No source this course cites reports a randomised comparison of amycretin against another active drug. The one quantitative cross-agent estimate is indirect: a network meta-analysis of amylin-based therapies that pooled six trials, 4642 participants in total, with follow-up ranging from 12 to 68 weeks. In its ranking, high-dose subcutaneous amycretin produced the largest reduction in percent body weight, a mean difference of -23.95% against placebo, ahead of high-dose eloralintide at -18.01% and high-dose CagriSema at -17.18%, all exceeding semaglutide 2.4 mg at -11.45%.

Modelled mean difference versus placebo, not weight loss

Three things are wrong with the obvious reading of that chart, and they compound. A mean difference is not a weight loss: it is the modelled gap against placebo, and where placebo gained weight the gap is larger than anything anyone lost. "High-dose subcutaneous amycretin" is a pooled stratum of two dose arms, not a dose, so no participant received a treatment with that result. And the whole thing is an indirect estimate, not a comparison. The near-match between -23.95% and the published -24.3% is a coincidence between two different quantities. Together with the estimand, covered below, that gives four questions to ask of any cross-agent weight figure, in this order: is it a loss or a difference, is it a dose or a pooled stratum, which estimand produced it, and was anything randomised between the two agents?

Is amycretin the strongest?
AdvancedWhy the comparison is tilted before it starts

The network used the longest available follow-up for each agent, a range of 12 to 68 weeks, so amycretin's arms are ranked against a semaglutide arm run for nearly twice as long. The estimands are mismatched too, and in the direction that flatters amycretin: the semaglutide trial reports a treatment-policy estimand, consistent with the intention-to-treat principle, which counts people who stopped treatment, while the amycretin subcutaneous inputs come from a trial whose sponsor described its matching figures as what would happen if all people adhered to treatment, and whose abstract reports a large number of withdrawals without giving the count.


Which hormones each agent engages


Amycretin versus CagriSema


The growing amylin family


Where amycretin is far behind